The genetic code of the most common type of hereditary breast cancer has been mapped for the first time, raising hopes for better diagnosis and treatment for the killer disease, scientists have said.
Researchers say they have "fully sequenced" the DNA of two breast cancers caused by a faulty BRCA1 gene, which is responsible for aggressive and highly drug-resistant tumours.
The team from the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research (ICR) say they hope that their work will lead to more tailored treatment for patients.
Dr Rachael Natrajan, one of the scientists involved in the study, said: "It is exciting to find new genes which could be involved in causing and driving breast cancer. Now these have been identified we have to do more work to find out the role that they play. Ultimately, this knowledge could help us develop new treatments that target the specific defects of each patient's disease."
Breast cancers genetically passed down through families account for up to 10% of all cases, affecting around 4,500 people in the UK each year.
The scientists said cases caused by the BRCA1 gene are "usually aggressive" and "do not benefit" from targeted drugs such as tamoxifen and herceptin.
The research, published in the Journal of Pathology, found that despite both tumours being caused by the same source they mutated in almost completely different ways.
Professor Jorge Reis-Filho, who co-authored the study, said: "We often consider patients with a faulty BRCA gene as one group but our work shows that each tumour can look very different from each other genetically. Now we understand this, we can start to identify the best treatment strategies to save more lives of hereditary breast cancer patients."
The study also included teams from the Institut Curie in France, the University Medical Centre Utrecht in the Netherlands, The Cancer Research UK London Research Institute in London and the University of Nottingham.
Last week the ICR, writing in the British Journal of Cancer, said all women under 50 who are diagnosed with triple-negative (TN) breast cancer should be screened for the BRCA1 gene fault, which also carries with it an additional high risk of developing ovarian cancer. It said the screening could identify hundreds of extra women every year who may benefit from tailored therapy.